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Abstract
Background: FOXC2 has lately been implicated in diabetes and obesity as well as mitochondrial function and
biogenesis and also as a regulator of mtTFA/Tfam. In this study, the expression of FOXC2 and selected genes
involved in mitochondrial function and biogenesis in healthy subjects and in a matched cohort with type 2
diabetes patients before and after treatment with rosiglitazone was determined. Quantitative real time PCR was
used to analyze both RNA and DNA from biopsies from subcutaneous adipose tissue.
Methods: Blood samples and subcutaneous abdominal fat biopsies were collected from 12 T2D patients, of which
11 concluded the study, pre-treatment and 90 days after initiation of rosiglitazone treatment, and from 19 healthy
control subjects on the first and only visit from healthy subjects. Clinical parameters were measured on the blood
samples. RNA and DNA were prepared from the fat biopsies and gene expression was measured with real time
PCR.
Results: The expression level of genes in the mitochondrial respiratory complexes I - IV were significantly
downregulated in the diabetic patients and restored in response to rosiglitazone treatment. Rosiglitazone
treatment also increased the relative number of mitochondria in diabetic patients compared with controls.
Furthermore, the transcription factors FOXC2 and mtTFA/Tfam displayed a response pattern identical to the
mitochondrial genes.
Conclusions: FOXC2, mtTFA/Tfam and subunits of the respiratory complexes I - IV show equivalent regulation in
gene expression levels in response to TZD treatment. This, together with the knowledge that FOXC2 has a
regulatory function of mtTFA/Tfam and mitochondrial biogenesis, suggests that FOXC2 has a possible functional
role in the TZD activated mitochondrial response.
Background
Insulin resistance is strongly associated with obesity and
a principal underlying defect in type 2 diabetes (T2D).
Insulin resistance also underpins the abnormalities asso-
ciated with the metabolic syndrome. Thiazolidinediones
(TZDs) are peroxisomal proliferator-activated receptor
(PPAR) - gamma agonists acting as powerful insulin
sensitizers with glucose lowering effects similar to
sulphonylureas and metformin. Apart from this, TZDs
have also been linked to a plethora of other effects such
as improved pro-coagulant state, blood pressure lower-
ing effects and anti-inflammatory activity [1,2]. While
some TZDs have been associated with impaired mito-
chondrial function [3] others have shown induction of
uncoupling protein-1 in white adipose tissue depots,
which would be compatible with enhanced mitochon-
drial activity [4].
The aim of this study was to analyze TZD mediated
effects on markers of mitochondrial function in adipose
tissue. We examined biopsies from healthy controls and
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a matched cohort of patients with type 2 diabetes prior
to and during treatment with rosiglitazone. Clinical vari-
ables such as blood pressure, fat mass and body mass
index (BMI) were compared as well as blood lipid and
insulin/glucose levels. From adipose tissue biopsies we
prepared DNA and total RNA, which enabled us to
compare the relative density of mitochondria as well as
expression levels of genes of the mitochondrial respira-
tory chain complexes I - IV, including NDUFS4, SDHA,
cytochrome b and COX II, and their responses to rosi-
glitazone treatment. We also analyzed the expression of
the nuclear-encoded mitochondrial transcription factor
A (mtTFA also referred to as Tfam), crucial in mito-
chondrial transcription and biogenesis [5-8], and
FOXC2, which lately has been implicated both as a pro-
moter of brown fat development and insulin sensitivity
[9-11], an important factor in mitochondrial function
and biogenesis [12] as well as a regulator of mtTFA/
Tfam expression [12].
Results
Clinical characteristics of the subjects and treatment
effects
There were no statistically significant differences between
the T2D patients at baseline and the control subjects in
BMI, fat mass and blood pressure. As expected, fasting
plasma glucose, serum insulin, HbA1c, HOMA-IR as well
as HS-CRP were clearly elevated in the T2D patients,
while adiponectin was suppressed. There was also a ten-
dency towards typical blood lipid abnormalities in the
T2D patients (low HDL, high free fatty acids and trigly-
cerides) but only the small reduction in total cholesterol
and HDL were statistically significant when compared
with the control subjects (Figures 1 and Additional file
1). Rosiglitazone treatment led to a small increase in BMI
and total cholesterol, as well as marked increases in adi-
ponectin and serum triglycerides, but reductions in
plasma glucose, HOMA-IR, HS-CRP, and systolic blood
pressure (Figure 1 and Additional file 1 and 2).
Mitochondrial number and steady state levels of mRNA
encoding mitochondrial respiratory chain proteins
To quantify and compare the relative numbers of mito-
chondria in the groups examined we set up a qrtPCR
assay to normalize the number of copies of the mito-
chondria encoded gene cytochrome b against the
nuclear encoded genes cyclophilin A and NRF1. This
ratio of genomic DNA derived form the nucleus and the
mitochondrion reflects the relative abundance of mito-
chondria in the collected tissue samples. While there
was no significant difference in this ratio when compar-
ing controls with T2D patients, there was a significant
increase in relative abundance of mitochondria as a con-
sequence of rosiglitazone treatment (Figure 2).
We investigated mRNA steady state levels of mito-
chondrial genes encoding proteins in the respiratory
chain. Levels of mRNA encoding members of complex I
(NDUFS4), II (SDHA), III (Cytochrome b) and IV (COX
II) were measured using real time PCR. As can be
deduced from Figure 3, there was a significant down
regulation of these genes in adipose tissue of patients
with T2D. In response to treatment this reduction is sig-
nificantly reversed for all genes measured except SDHA
of complex II. Furthermore, there was a significant cor-
relation between the expression of the mitochondrial
genes NDUFS4, Cytochome b, COX II and mtTFA/
Tfam and the levels of adiponectin, insulin and glucose.
The gene expression level of SDHA significantly corre-
lated with the glucose and insulin, but not adiponectin
levels (data not shown).
We also investigated mRNA levels for NRF1, PGC1a,
mtTFA/Tfam as well as FOXC2, a forkhead family tran-
scription factor, previously shown to increase the
amount of mitochondria rich brown adipose tissue
[9,11], and to stimulate mitochondrial function and bio-
genesis [12]. There was a significant decrease in mRNA
levels of NRF1 when control subjects and T2D patients
were compared (Figure 4), but there was no regulation
in response to treatment. In the case of PGC1a no sig-
nificant regulation was seen. On the other hand, FOXC2
and mtTFA/Tfam levels were significantly down regu-
lated in the T2D cohort and significantly up regulated
in response to treatment, thus mimicking the expression
profiles of respiratory chain subunits (Figure 4).
Discussion
Thiazolidinediones improve insulin resistance by enhan-
cing insulin action in skeletal muscle, liver and adipose
tissue through a mechanism that is not yet fully under-
stood. Whereas biochemically TZDs are ligands for
PPARg and previous studies suggest that there is a cor-
relation between anti-diabetic effect and PPARg activa-
tion, some studies imply that also receptor independent
TZD effects might contribute, as reviewed by Feinstein
et al. [3]. In this study, we addressed the question of
TZD related effects on mitochondrial function in
human adipose tissue biopsies. Three groups were com-
pared: healthy control subjects and a group of matched
patients with non-symptomatic T2D on stable treatment
with diet and/or hypoglycemic agents (not TZD) prior
to and after treatment with rosiglitazone for 90 days.
While an increase in BMI was noted during treatment
no increase in fat mass was observed (Figure 1). This is
most likely a consequence of peripheral fluid retention,
a well-known side effect of TZD treatment [13]. Systolic
but not diastolic blood pressure was lowered in the trea-
ted group, a finding that agrees well with other studies
that implicate a more pronounced lowering-effect on
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systolic pressure as compared with diastolic [14]. Also,
the well-documented anti-inflammatory effect of TZD
treatment, which may be in part mediated by increased
adiponectin levels and visualized as a reduction in levels
of C-reactive protein (Figure 1), can promote anti-ather-
osclerotic effects [15]. It cannot be ruled out that other
factors, like physical activity, could contribute to the
changes in the rosiglitazone-treated group, but the
Figure 1 Clinical characterization and treatment effects. The clinical variables BMI (a), FMPC (b),adiponectin (c), CRP (d), glucose (e) and
insulin (f) of the healthy controls and diabetic patients before and after treatment with rosiglitazone for 90 days. Bars represent mean and error
bars SEM. * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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patients did not report changes in their lifestyles when
asked.
Using a PCR based method we measured levels of
mtDNA as well as nuclear DNA as described under
“material and methods”. This enabled us to calculate the
ratio of mtDNA normalized against nuclear DNA
reflecting the relative number of mitochondria. There
was a significant increase in the relative amount of
mtDNA when controls and treated patients were com-
pared (Figure 4). This agrees well with earlier studies
demonstrating that in response to pioglitazone patients
with T2D increase levels of mtDNA in subcutaneous
adipose tissue [16,17]. In the present study we extend
what is known about TZD induced effects on mitochon-
drial function by not only measuring relative mtDNA
levels but also steady state levels of mitochondria
encoded subunits of respiratory complexes. In Figure 4
we demonstrate that subunits derived from complex I,
II, III and IV are all significantly down regulated in
patients with T2D. After rosiglitazone treatment,
expression levels of these subunits were normalized or
near normalized. This extends previous findings in
which genes involved in oxidative metabolism have been
shown to be positively regulated by TZDs [16]. Here we
demonstrate that the mitochondrial genome in human
adipose tissue, directly or indirectly, responds to rosigli-
tazone treatment as judged by regulation of respiratory
chain subunits.
Another interesting finding is the co-variation of adi-
ponectin levels with the profile of respiratory chain
complexes. This has actually been suggested based on
experiments in mice and using cell lines [18]. Thus, a
possible regulatory role involving the mitochondria in
regulation of adiponectin levels cannot be excluded, and
by the experiments presented here this notion can be
extended to include human adipose tissue. PGC1a has
been shown to be positively regulated by TZDs and sup-
pressed during insulin resistance [16,19]. In this study,
we see a trend towards increased levels in response to
rosiglitazone treatment but no difference between
Figure 2 Number of mitochondria in controls and patients with type II diabetes. Real-time PCR quantification of the number of
mitochondria based on quantification of the mitochondria encoded gene cytochrome b and the nuclear encoded genes cyclophilin A and NRF-
1. Bars represent mean and error bars SEM. * = p < 0.05.
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Figure 3 mRNA levels of genes coding for subunits in the electron transport chain. Relative expression levels of genes coding for subunits
of the electron transport chain in healthy controls and diabetic patients before and after treatment with rosiglitazone for 90 days. (a) NDUFS4 in
complex I, (b) SDHA in complex II, (c) cytochrome b in complex III, (d) COX Vb in complex III, (e) COX II in complex IV. Bars represents mean and
error bars SEM. * = p < 0.05, ** = p < 0.01.
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control and untreated T2D subjects. While in our mate-
rial we see a significant down regulation of NRF1 in
T2D patients, as has previously been reported [20],
there is no significant regulation of PGC1a (Figure 4).
This is in contrast to studies showing that PGC1a is
positively regulated by TZDs and suppressed during
insulin resistance [16,21]. The lack of TZD mediated
regulation of NRF1 in adipose tissue gains support from
a study by Bogacka et al. [16].
We also demonstrate that the transcription factor
FOXC2 is subjected to significant regulation. This is
interesting since FOXC2 has been implicated as a regu-
lator of the amount of brown fat in rodents and also to
increase the number of mitochondria and the
mitochondrial function in response to its up-regulation
[9,10,12]. Previously, we have shown reduced levels of
FOXC2 in adipose tissue of insulin resistant subjects
[11] and here we extend this observation to also include
TZD-mediated regulation. Thus, FOXC2, previously
linked to increased mitochondrial numbers in mice [9],
is downregulated in patients with T2D and upregulated
in response to TZD treatment. The profile of FOXC2
regulation, as depicted in Figure 4, matches that of adi-
ponectin and those of the respiratory chain complex
subunits.
Furthermore, we recently showed that FOXC2 has a
regulatory function of mtTFA/Tfam [12], crucial for
mitochondrial transcription and biogenesis [5-8]. In the
Figure 4 mRNA levels of NRF1, FOXC2, PGC1a and mtTFA/Tfam. Relative mRNA expression levels of NRF1 (a), PGC1a (b), FOXC2 (c) and
mtTFA/Tfam (d) in healthy controls and diabetic patients before and after treatment with rosiglitazone for 90 days. Bars represent mean and
error bars SEM. * = p < 0.05.
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present study we show the same transcriptional regulation
of FOXC2 and mtTFA/Tfam in diabetic patients com-
pared to healthy controls and in response to rosiglitazone
treatment. Together, this not only establishes FOXC2 as a
TZD responsive gene but it also suggests that FOXC2, in
support of other evidence [12], plays a role in mitochon-
drial gene regulation in human adipose tissue.
In conclusion, the equivalent regulation in gene
expression of FOXC2, mtTFA/Tfam and subunits of the
respiratory complexes I - IV, in response to TZD treat-
ment, together with the knowledge that FOXC2 has a
regulatory function of mtTFA/Tfam and mitochondrial
biogenesis, suggests a possible functional role for
FOXC2 in the TZD activated mitochondrial response.
Materials and methods
The regional ethical review board approved this explora-
tive open trial, which was carried out in accordance with
the principles of the Declaration of Helsinki. Informed
consent was obtained from all patients.
Subjects and treatment
We recruited 12 T2D patients (including 11 men and
one woman) and 19 healthy control subjects (including
16 men and three post-menopausal women) via a news-
paper advertisement. Patients on treatment with diet or
oral hypoglycemic agents participated, and rosiglitazone
8 mg QD was added to the treatment regimen in accor-
dance with the approved label. Before the study, three
patients were on diet treatment, three on sulfonylurea,
two on repaglinide, two on metformin and one on sulfo-
nylurea and metformin combined.
Clinically significant diseases or symptoms, such as
ischemic heart disease and thyroid disease as well as
HbA1c > 10% were exclusion criteria. Seven patients
were treated with antihypertensive agents and four with
statins against hyperlipidemia. All patients were non-
smokers but one subject used moist snuff. The patients
were encouraged not to change their lifestyle habits dur-
ing the study. One lean untreated patient (BMI 20) had
previously been diagnosed as type 2 diabetic on clinical
grounds but was excluded due to low serum insulin and
C-peptide levels as well as rapidly deteriorating glycemic
control. Thus, the results are based on the 11 patients
who concluded the 90 days treatment period.
The healthy control subjects, who were individually
matched to the patients with diabetes according to age
and BMI, were all non-smokers but one subject used
moist snuff. One subject was treated with an antihyper-
tensive agent and one with a statin for hyperlipidemia.
Clinical procedures
Blood samples and abdominal fat biopsies were collected
pre-treatment and 90 days after initiation of
rosiglitazone treatment from the diabetic patients, and
on the first and only visit from healthy subjects. All
blood sampling and examinations were done in the
morning after an overnight fast and before the partici-
pants had taken any of their daily medication. The biop-
sies (approximately 300 mg) were taken from the
subcutaneous adipose tissue in the paraumbilical region
after local infiltrative anesthesia with lidocaine (10 mL,
0.5%). Plasma glucose, serum insulin and blood lipids
were analyzed using standard laboratory methods.
HbA1c was determined using high-performance liquid
chromatography (Mono-S method). In this study, all
HbA1c values were converted to NGSP standard levels
using the formula: HbA1c (NGSP) = (0.923 × HbA1c
(Mono-S) + 1.345 (R2 = 0.998)[22]. High-sensitive C-
reactive protein (HS-CRP) was analyzed with an immu-
noturbidimetric method. Total adiponectin was mea-
sured using the Human Adiponectin ELISA Kit (B-
Bridge International, BioCat, GmbH, Germany). The
proportion of body fat was determined using bioelectri-
cal impedance (single frequency, 50 kHz; Animeter,
HTS, Odense, Denmark). Blood pressure was measured
in the supine position as a mean (mmHg) of two read-
ings (Korotkoff 1 - 5), using a cuff of appropriate size.
RNA and DNA isolation and cDNA synthesis
Total RNA was isolated from approximately 200 mg fat
tissue with the RNeasy Lipid Tissue Mini kit (Qiagen)
and treated with RNase free DNase (Qiagen) according
to the manufacturer’s protocol. The RNA concentration
was measured on a Nanodrop ND-1000 (Saveen Wer-
ner). DNA was isolated from approximately 100 mg fat
tissue using the Wizard Genomic DNA purification kit
(Promega) according to the manufacturer’s protocol.
The 1st Strand cDNA Synthesis kit for RT-PCR (AMV)
(Roche) was used for reverse transcription of 500 ng
total RNA using a mix of random primer p(dN)6 and
oligo dT15.
Quantitative real time PCR
All real-time PCR assays contained 13 μl SYBR green
PCR Master Mix (2×) (Applied Biosystems), 9 μl H2O,
1.5 μl of each forward and reverse primer (20 μM) and
1 μl cDNA or genomic DNA, except for FOXC2 for
which the following composition was used: 13 μl Taq-
Man 2× Universal Master Mix (Applied Biosystems),
9.95 μl H2O, 0.65 μl forward primer (13 μM), 0.9 μl
reverse primer (13 μM), 0.5 μl probe (5 μM) and 1 μl
cDNA. The real-time PCR was performed with an ABI
PRISM 7900HT (Applied Biosystems) with the following
incubations: 50°C for 2 minutes, 95°C for 10 minutes
and then 40 cycles of 95°C for 15 seconds and 60°C for
1 minute. Expected PCR products were confirmed on
agarose gel electrophoresis (2%) and melting curve
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analysis. Real-time PCR was run on genomic and mito-
chondrial DNA to quantify the number of genomic
copies, and on cDNA made from mRNA to quantify the
number of transcripts. The real-time PCR primers were
designed using Primer3 http://frodo.wi.mit.edu/primer3/.
The following primers were used on genomic DNA:
Cytochrome b fwd 5’-tatccgccatcccatacatt-3’ rev: 5’-
ggtgattcctagggggttgt-3’, Cyclophilin A fwd 5’-ttcatctg-
cactgccaagac-3’ rev 5’-tcgagttgtccacagtcagc3’, NRF1 fwd
5’-gtccagatccctgtgagcat-3’rev 5’-caatgtcaccacctccacag-3.
Primers used on cDNA were: Cytochrome b fwd 5’-caa-
catctccgcatgatgaaa-3’ rev 5’-ccataatttacgtctcgagtgatgtg-3’,
Cyclophilin A fwd 5’-catctgcactgccaagactga-3’rev 5’-
ttcatgccttctttcactttgc-3’, NRF1 fwd 5’-cctccaaacc-
taaccctgtcttta-3’rev 5’-cttccaggatcatgctcttgtactt-3’, b-actin
fwd 5’-gagctacgagctgcctgacg-3’rev 5’-gtagtttcgtggatgcca-
cag-3, PGC1a fwd 5’-gccaaaccaacaactttatctcttc-3’ rev 5’-
cacacttaaggtgcgttcaatagtc-3’, NDUFS4 fwd 5’-tccaa-
gaaaagtttgcacca-3’ rev 5’-cgcaataacatgcagtctgg-3’, COX II
fwd 5’-tgaagcccccattcgtataa-3’ rev 5’-atgggcat-
gaaactgtggtt-3’, COX Vb fwd 5’- actgggttggagagggagat-3’
rev 5’-agacgacgctggtattgtcc-3’, SDHA fwd 5’-tgggaacaa-
gagggcatctg-3’ rev 5’- ccaccactgcatcaaattcatg-3’, FOXC2
fwd 5’-gcccagcagcaaactttcc-3’rev 5’-cccgagggtcgagttctca-
3’ probe 5’-tgttcaactcccaccggctggg-3’, mtTFA/Tfam fwd
5’- gggttccagttgtgattgct-3’ rev 5’- gccaagacagatgaaaacca-
3’.
Calculations and statistics
In a PCR assay, the relative number of mitochondria
was determined by measuring mtDNA as the level of
the mitochondrial gene cytochrome b and normalizing
it, by geometric averaging, against nuclear DNA mea-
sured as the level of cyclophilin A and NRF-1. Similar
methodology has been used by others [16]. To quantify
the number of transcripts, the mRNA levels were nor-
malized against cyclophilin A and b-actin by geometric
averaging. All PCR reactions were run in triplicates and
the mean Ct-values were used. For statistical calculations
Mann-Whitney U-test, Wilcoxon’s matched pairs signed
rank sum test and Student’s t-test were used as appro-
priate. The correlation was analyzed on all subjects,
according to Spearman.
Additional material
Additional file 1: Clinical variables I. The clinical variables systolic
pressure (a), diastolic pressure (b), the calculated value for HOMA-IR (c)
and Hba1c (d) of the healthy controls and diabetic patients before and
after treatment with rosiglitazone for 90 days. Bars represent mean and
error bars SEM. * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
Additional file 2: Clinical variables II. The clinical variables cholesterol
(a), LDL (b), HDL (c), free fatty acids (d) and triglycerides (e) of the
healthy controls and diabetic patients before and after treatment with
rosiglitazone for 90 days. Bars represent mean and error bars SEM. * = p
< 0.05.
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